Literature DB >> 15243793

Cytotoxic chemotherapy administered to two patients with partially refractory leukaemia while receiving intensive care treatment.

K A Al-Anazi1, S Jacobs.   

Abstract

Administration of cytotoxic chemotherapy to a mechanically ventilated patient is a major undertaking. Induction of remission of leukaemia under such circumstances is an extremely rare event. We report two patients with partially refractory acute myeloid leukaemia who achieved remission of their leukaemia after receiving chemotherapy in the intensive care unit. Both patients were subsequently cured by allogeneic bone marrow transplant.

Entities:  

Mesh:

Year:  2004        PMID: 15243793     DOI: 10.1007/s00520-004-0665-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  23 in total

1.  Prognosis in acute organ-system failure.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Ann Surg       Date:  1985-12       Impact factor: 12.969

2.  Outcome of mechanical ventilation for adults with hematologic malignancy.

Authors:  D E Epner; P White; M Krasnoff; S Khanduja; K T Kimball; W A Knaus
Journal:  J Investig Med       Date:  1996-06       Impact factor: 2.895

3.  Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support.

Authors:  E Azoulay ; C Alberti ; C Bornstain ; G Leleu ; D Moreau ; C Recher ; S Chevret ; J R Le Gall ; L Brochard; B Schlemmer
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

4.  Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma.

Authors:  J D Nosanchuk; K A Sepkowitz; R N Pearse; M H White; S D Nimer; D Armstrong
Journal:  Bone Marrow Transplant       Date:  1996-08       Impact factor: 5.483

5.  Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT.

Authors:  K Godder; A Pati; S Abhyankar; A P Gee; R Parrish; C Lee; P J Henslee-Downey
Journal:  Bone Marrow Transplant       Date:  1996-01       Impact factor: 5.483

6.  Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.

Authors:  E Feldman; M Kalaycio; G Weiner; S Frankel; P Schulman; L Schwartzberg; J Jurcic; E Velez-Garcia; K Seiter; D Scheinberg; D Levitt; N Wedel
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

7.  Precedents for meaningful recovery during treatment in a medical intensive care unit. Outcome in patients with hematologic malignancy.

Authors:  D P Schuster; J M Marion
Journal:  Am J Med       Date:  1983-09       Impact factor: 4.965

8.  Treatment of acute respiratory failure by helmet-delivered non-invasive pressure support ventilation in children with acute leukemia: a pilot study.

Authors:  Marco Piastra; Massimo Antonelli; Antonio Chiaretti; Giancarlo Polidori; Lorenzo Polidori; Giorgio Conti
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

9.  Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients.

Authors:  Michael Darmon; Elie Azoulay; Corinne Alberti; Fabienne Fieux; Delphine Moreau; Jean-Roger Le Gall; Benoît Schlemmer
Journal:  Intensive Care Med       Date:  2002-10-25       Impact factor: 17.440

10.  How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration.

Authors:  G Meloni; S M Trisolini; S Capria; G F Torelli; E Baldacci; C Torromeo; G Valesini; F Mandelli
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.